Alexion completes Phase II pexelizumab enrollment

ALXN and partner Procter & Gamble (PG) completed enrollment in a placebo-controlled dose-ranging Phase II trial of pexelizumab C5 complement inhibitor antibody fragment to treat acute myocardial infar...